Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer:...
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
About this item
Full title
Author / Creator
Vergnenègre, Alain , Basse, Victor , Le Garff, Gwenaelle , Bylicki, Olivier , Dubos-Arvis, Catherine , Comet, Bénédicte , Marcq, Marie , Le Treut, Jacques , Auliac, Jean-Bernard , Madroszyk, Anne , Fraboulet, Gislaine , Crequit, Jacky , Thomas, Pascal , Paleiron, Nicolas , Monnet, Isabelle and French Lung Cancer Group
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Antiangiogenic agents have improved the prognosis of non-squamous non-small-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small-cell...
Alternative Titles
Full title
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_90fe7363d9464daf9d60998ae09f8b6c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_90fe7363d9464daf9d60998ae09f8b6c
Other Identifiers
ISSN
1179-1322
E-ISSN
1179-1322
DOI
10.2147/CMAR.S219984
